Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/15219
Association Between Body Size Phenotypes and Subclinical Atherosclerosis
Identifiers
ISSN: 0021-972X
eISSN: 1945-7197
WOS ID: 000584547800050
Scopus EID: 2-s2.0-85092120313
PMID: 32879953
Embase PUI: L2010072475
Share
Statistics
Item usage statisticsMetadata
Show Dublin Core item recordPublication date
2020-12Document type
research articleCitation
Rossello Lozano FJ, Fuster V, Oliva B, Sanz J, Fernandez Friera LA, Lopez-Melgar B, et al. Association Between Body Size Phenotypes and Subclinical Atherosclerosis. J Clin Endocrinol Metab. 2020 Dec;105(12):dgaa620.Abstract
Context: The underlying relationship between body mass index (BMI), cardiometabolic disorders, and subclinical atherosclerosis is poorly understood. Objective: To evaluate the association between body size phenotypes and subclinical atherosclerosis. Design: Cross-sectional. Setting: Cardiovascular disease-free cohort. Participants: Middle-aged asymptomatic subjects (n = 3909). A total of 6 cardiometabolic body size phenotypes were defined based on the presence of at least 1 cardiometabolic abnormality (blood pressure, fasting blood glucose, triglycerides, low high-density lipoprotein cholesterol, homeostasis model assessment-insulin resistance index, high-sensitivity C-reactive protein) and based on BMI: normal-weight (NW; BMI <25), overweight (OW; BMI = 25.0-29.9) or obese (08; BMI >30.0). Main Outcome Measures: Subclinical atherosclerosis was evaluated by 2D vascular ultrasonography and noncontrast cardiac computed tomography. Results: For metabolically healthy subjects, the presence of subclinical atherosclerosis increased across BMI categories (49.6%, 58.0%, and 67.7% for NW, OW, and OB, respectively), whereas fewer differences were observed for metabolically unhealthy subjects (61.1%, 69.7%, and 70.5%, respectively). When BMI and cardiometabolic abnormalities were assessed separately, the association of body size phenotypes with the extent of subclinical atherosclerosis was mostly driven by the coexistence of cardiometabolic risk factors: adjusted OR = 1.04 (95% confidence interval [CI), 0.90-1.19) for OW and OR = 1.07 (95% CI, 0.88-1.30) for OB in comparison with NW, whereas there was an increasing association between the extent of subclinical atherosclerosis and the number of cardiometabolic abnormalities: adjusted OR = 1.21 (95% CI, 1.05-1.40),1.60 (95% Cl, 1.33-1.93), 1.92 (95% CI, 1.48-2.50), and 2.27 (95% Cl, 1.67-3.09) for 1, 2, 3, and >3, respectively, in comparison with noncardiometabolic abnormalities. Conclusions: The prevalence of subclinical atherosclerosis varies across body size phenotypes. Pharmacologic and lifestyle interventions might modify their cardiovascular risk by facilitating the transition from one phenotype to another.
Publisher version
https://dx.doi.org/10.1210/clinem/dgaa620MeSH
SpainAdult
Humans
Body Size
Middle Aged
Cross-Sectional Studies
Asymptomatic Diseases
Phenotype
Male
Female
Risk Factors
Atherosclerosis
Cohort Studies
Prevalence
DeCS
Estudios de CohortesEnfermedades Asintomáticas
Prevalencia
Tamaño Corporal
Femenino
Masculino
Aterosclerosis
Estudios Transversales
Factores de Riesgo
Humanos
Persona de Mediana Edad
Fenotipo
Adulto
España
This item appears in following Docusalut collections
Hospital Universitario Son Espases - HUSE > Comunicación científicaInstituto de Investigación Sanitaria Islas Baleares - IDISBA > Comunicación científica